CIA
FATE icon

Capital Impact Advisors’s Fate Therapeutics FATE Stock Holding History

Capital Impact Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-45,738
Closed -$218K – 131
2023
Q2 		$218K Buy
45,738
+4,421
+11% +$24.4K 0.24% 153
2023
Q1 		$236K Buy
41,317
+22,860
+124% +$138K 0.29% 143
2022
Q4 		$186K Sell
18,457
-1,816
-9% -$34.1K 0.18% 191
2022
Q3 		$408K Buy
20,273
+3,747
+23% +$108K 0.41% 100
2022
Q2 		$410K Sell
16,526
-2,323
-12% -$64.1K 0.38% 122
2022
Q1 		$731K Buy
18,849
+8,649
+85% +$335K 0.53% 84
2021
Q4 		$597K Buy
+10,200
New +$578K 0.41% 74
2021
Q1 		– Sell
-32,000
Closed -$2.91M – 117
2020
Q4 		$2.91M Buy
+32,000
New +$1.99M 0.71% 61

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital Impact Advisors's FATE Position: Q3 2023 in Review

Capital Impact Advisors sold out of Fate Therapeutics (FATE) in Q3 2023, closing a stake of 45,738 shares — an estimated $218K sold.

Capital Impact Advisors first reported a position in FATE in Q4 2020 and held it in 8 quarters. The position peaked at $2.91M in Q4 2020. 170 funds tracked by Wall St. Rank hold FATE as of Q3 2023.

  • Capital Impact Advisors reported no remaining Fate Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Capital Impact Advisors sold 45,738 Fate Therapeutics shares in Q3 2023, an estimated $218K.
  • Capital Impact Advisors first reported a position in Fate Therapeutics in Q4 2020 and held it in 8 quarters.
  • Capital Impact Advisors's Fate Therapeutics position peaked at $2.91M in Q4 2020.
  • 170 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2023.

Based on Capital Impact Advisors's 13F filing for Q3 2023, filed 15 Nov 2023.